Physician

Sudheer R Ummadi, MD

According to 2025 Medicare claims, Sudheer Ummadi, MD (NPI: 1437118106) practices internal medicine in the Detroit-Dearborn-Livonia, MI market, with the plurality of this provider's patient population coming from Wayne, MI. This provider's primary affiliated billing organization is NEPHROLOGY HYPERTENSION CLINIC, PC (NPI: 1053466094; TIN: 383004074) and primary practice location at 48101-2503.

Ummadi's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 831 traditional Medicare patients, billed 15,224 HCPCS/CPT codes, and received $704,756 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 3,534 prescription claims across 706 beneficiaries totaling $694,849 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 104 claims. Open Payments data shows 89 records totaling $2,257. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $846,163 and ending at $704,756. Concurrently, Part D prescription costs have risen steadily, from $334,986 to $694,849. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $461 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,039	4,035	$846,163
2016	1,068	4,379	$852,631
2017	966	4,000	$591,807
2018	938	6,845	$495,685
2019	1,080	23,305	$821,042
2020	1,034	21,545	$952,691
2021	916	24,064	$1,038,535
2022	851	14,009	$807,943
2023	813	11,883	$648,427
2024	831	15,224	$704,756

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	309	1,621	$334,986
2016	363	2,376	$459,197
2017	344	2,214	$328,622
2018	339	2,052	$203,877
2019	421	2,410	$381,514
2020	465	2,710	$358,832
2021	525	2,823	$423,514
2022	599	3,154	$455,098
2023	633	3,298	$718,069
2024	706	3,534	$694,849

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	60	$2,678
2016	N/R	118	$5,233
2017	N/R	178	$6,439
2018	N/R	117	$4,543
2019	N/R	97	$2,596
2020	N/R	122	$3,015
2021	N/R	128	$2,720
2022	N/R	138	$3,022
2023	N/R	152	$4,280
2024	N/R	104	$2,609

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	111	658	$283
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	113	128	$104
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	248	886	$63
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	335	674	$43
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	129	11,290	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	105	6,420	$118,273
Cinacalcet Hcl	Cinacalcet Hcl	54	3,690	$51,348
Jardiance	Empagliflozin	37	2,310	$42,289
Lokelma	Sodium Zirconium Cyclosilicate	38	1,682	$38,294
Veltassa	Patiromer Calcium Sorbitex	27	1,378	$36,852

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7515	Cyclosporine, oral, 25 mg	N	N/R	12	$960
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	35	$640
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	18	$555
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	22	$238
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	17	$216

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	89	$2,257	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sudheer R. Ummadi, MD?

Tedicare shows public-source Medicare data for Sudheer R. Ummadi, MD (NPI 1437118106), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sudheer R. Ummadi, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Sudheer R. Ummadi, MD?

Sudheer R. Ummadi, MD is linked to NEPHROLOGY HYPERTENSION CLINIC, PC (billing NPI 1053466094) in the available physician profile data.

Does Sudheer R. Ummadi, MD have Open Payments data?

Sudheer R. Ummadi, MD has 89 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.